Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BIM-DRS Low Dose
BIM-DRS · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Bimatoprost-Drug Ring System Low Dose and Previously Implanted Commercially Available Monofocal IOL | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System High Dose and Previously Implanted Commercially Available Monofocal IOL | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System Low Dose with SpyGlass IOL (IOL with silicone pads (no drug)) | EXPERIMENTAL | - |
| Bimatoprost-Drug Ring System High Dose with SpyGlass IOL (IOL with silicone pads (no drug)) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BIM-DRS Low Dose | DRUG | Bimatoprost-Drug Ring System Low Dose |
| BIM-DRS High Dose | DRUG | Bimatoprost-Drug Ring System High Dose |
| SpyGlass IOL with silicone pads (no drug) | DEVICE | SpyGlass Intraocular Lens with silicone pads (no drug) |
Inclusion Criteria: * Diagnosis of mild to moderate open-angle glaucoma or ocular hypertension * Pseudophakic or planned removal of cataract * Female participants of childbearing potential must have a negative urine pregnancy test at the baseline visit and agree to the use of contraception Exclusi...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
BIM-DRS is an investigational small molecule developed by SpyGlass Pharma, Inc. for glaucoma. It is being studied as a drug ring system in pseudophakic patients diagnosed with open angle glaucoma or ocular hypertension. It is in Phase 1 clinical development and is also referred to as BIM-DRS Low Dose.
BIM-DRS is being developed to treat open angle glaucoma and ocular hypertension in pseudophakic patients. The Phase 1 trial enrolls adults aged 22 years and older with these diagnoses. It is investigational and has not been approved for commercial use.
BIM-DRS targets PTGER2, the prostaglandin E2 receptor subtype EP2. PTGER2 is a G protein coupled receptor involved in prostaglandin signaling. BIM-DRS is a small molecule designed to act on this target as part of a drug ring system being evaluated in glaucoma.
BIM-DRS is developed by SpyGlass Pharma, Inc., which trades under the ticker SGP. The company is advancing the drug ring system as its investigational candidate for open angle glaucoma and ocular hypertension in pseudophakic patients.
BIM-DRS is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The single Phase 1 trial is currently active and not yet recruiting, with a planned enrollment of 24 participants.
BIM-DRS is being evaluated in one Phase 1 trial, NCT07641296, titled Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension. The trial is active, not yet recruiting, and plans to enroll 24 participants.
Yes, BIM-DRS Low Dose is an alternative name for BIM-DRS. Both refer to the same investigational small molecule drug ring system developed by SpyGlass Pharma, Inc. for open angle glaucoma and ocular hypertension in pseudophakic patients.